GlassScriptPhysician profile
James G Hueftle
NPI 1528041571
$5,221.12
in general payments reported to CMS, 2019-2025
38 companies · $395 in 2025
The $395 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,250 · 2020: $1,188 · 2021: $275 · 2022: $976 · 2023: $520 · 2024: $618 · 2025: $395.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,503 · Education: $29.09.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,503.41 |
| Education | $29.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $931.78 | 2019-2025 | Calquence, Datroway |
| E.R. Squibb & Sons, L.L.C. | $632.27 | 2019-2023 | Opdivo, Sprycel |
| Amgen INC. | $476.30 | 2019-2024 | Imdelltra (Amg 757) |
| Janssen Biotech, INC. | $315.32 | 2022-2024 | Rybrevant |
| Emd Serono, INC. | $285.62 | 2023-2024 | Bavencio |
| Genzyme Corporation | $219.76 | 2019-2023 | |
| Glaxosmithkline, LLC. | $198.86 | 2020-2024 | Ojjaara |
| Merck Sharp & Dohme LLC | $191.97 | 2019-2024 | Keytruda |
| Exelixis INC. | $178.53 | 2020-2022 | |
| Novartis Pharmaceuticals Corporation | $140.85 | 2019-2023 | |
| Alexion Pharmaceuticals, INC. | $130.54 | 2019 | |
| Janssen Scientific Affairs, LLC | $122.58 | 2022-2023 | Imbruvica, Tecvayli, Darzalex |
| Regeneron Healthcare Solutions, INC. | $120.97 | 2022 | |
| Eisai INC. | $114.78 | 2019-2020 | |
| Genentech USA, INC. | $105.02 | 2019-2020 |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $96.21 | 2025 | Breyanzi |
| Seagen INC. | $95.72 | 2019-2020 | |
| Astellas Pharma US INC | $95.41 | 2019-2020 | |
| Genentech, INC. | $95.12 | 2025 | Itovebi |
| Pfizer INC. | $90.23 | 2019-2020 | |
| Caris Mpi, INC. | $85.34 | 2025 | Mi Cancer Seek |
| Adaptive Biotechnologies Corporation | $77.25 | 2024 | Clonoseq |
| Kite Pharma, INC. | $67.85 | 2023 | |
| Myriad Genetic Laboratories, INC. | $57.73 | 2022 | |
| Genmab U.S., INC. | $56.29 | 2025 | Epkinly |
| Takeda Pharmaceuticals U.S.A., INC. | $41.40 | 2019-2020 | |
| Tesaro, INC. | $29.35 | 2019 | |
| Novo Nordisk INC | $25.77 | 2019-2022 | |
| Pharmacyclics LLC, An Abbvie Company | $24.61 | 2019-2020 | |
| Foundation Medicine, INC. | $15.65 | 2019 | |
| Aveo Pharmaceuticals, INC. | $15.50 | 2021 | |
| Incyte Corporation | $13.62 | 2020 | |
| Clovis Oncology, INC. | $12.75 | 2019 | |
| Lilly USA, LLC | $12.69 | 2019 | |
| Agios Pharmaceuticals, INC. | $12.36 | 2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $11.82 | 2019 | |
| Puma Biotechnology, INC. | $11.80 | 2019 | |
| Tolmar Pharmaceuticals, INC. | $11.50 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Hueftle listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.